Nigeria has recorded a major advance in HIV prevention with the arrival of a long-acting injectable medicine designed to reduce the risk of infection.
The National AIDS, Viral Hepatitis and STIs Control Programme (NASCP), under the Federal Ministry of Health and Social Welfare, confirmed that the first shipment of long-acting injectable Lenacapavir for pre-exposure prophylaxis (PrEP) landed in the country on 10 March 2026.
Health officials say the injectable, which offers extended protection compared with daily oral PrEP, could greatly improve adherence among people at higher risk of HIV infection.
Daily pill regimens have long posed challenges for some users due to stigma, forgetfulness and access issues.
READ ALSO: India Declines Tinubu’s Ambassador Nominee
The rollout is being supported by the Global Fund, and is expected to widen prevention choices while improving access to HIV services, particularly for populations who struggle with regular medication schedules.
In a statement, NASCP said the arrival of the injectable marks a step forward in strengthening HIV prevention services and reducing new infections nationwide.
Dr Adebobola Bashorun, Federal Director and National Coordinator of NASCP, said the development reflects the government’s commitment to deploying innovative tools to curb the spread of HIV, while reinforcing testing, treatment and long-term care.
Programme officials added that the drug will be carefully integrated into Nigeria’s national HIV prevention strategy, working closely with partners and stakeholders to ensure safe, effective and equitable deployment across the country.